world
Monday Nov 22 2021
By
Reuters

Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents

By
Reuters
An Israeli health worker displays a vial of the Pfizer/BioNTech COVID-19 vaccine for children, at the Meuhedet Healthcare Services Organisation in Tel Aviv on November 22, 2021. — AFP
An Israeli health worker displays a vial of the Pfizer/BioNTech COVID-19 vaccine for children, at the Meuhedet Healthcare Services Organisation in Tel Aviv on November 22, 2021. — AFP

  • A two-dose series of vaccine was 100% effective against COVID-19.
  • It was measured 7 days through over 4 months after second dose.
  • Vaccine was authorised for emergency use in people aged 12-15 years by US in May.


Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorised for emergency use in people aged 12-15 years by the US Food and Drug Administration in May, and granted full approval for use in people aged 16 and above in August.